GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Price-to-Owner-Earnings

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Price-to-Owner-Earnings : (As of Jun. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Price-to-Owner-Earnings?

As of today (2024-06-05), Parnell Pharmaceuticals Holdings's share price is $0.0001. Parnell Pharmaceuticals Holdings does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Parnell Pharmaceuticals Holdings's Price-to-Owner-Earnings or its related term are showing as below:


PARNF's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 25.855
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-05), Parnell Pharmaceuticals Holdings's share price is $0.0001. Parnell Pharmaceuticals Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2018 was $0.01. Therefore, Parnell Pharmaceuticals Holdings's PE Ratio for today is 0.01.

As of today (2024-06-05), Parnell Pharmaceuticals Holdings's share price is $0.0001. Parnell Pharmaceuticals Holdings's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.11. Therefore, Parnell Pharmaceuticals Holdings's PE Ratio without NRI for today is At Loss.


Parnell Pharmaceuticals Holdings Price-to-Owner-Earnings Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Price-to-Owner-Earnings Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Price-to-Owner-Earnings Get a 7-Day Free Trial - - - - -

Competitive Comparison of Parnell Pharmaceuticals Holdings's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parnell Pharmaceuticals Holdings's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's Price-to-Owner-Earnings falls into.



Parnell Pharmaceuticals Holdings Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Parnell Pharmaceuticals Holdings's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0001/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Parnell Pharmaceuticals Holdings  (OTCPK:PARNF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Parnell Pharmaceuticals Holdings Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.